Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636105 | 1.00 | PDPK1 (0.38) | PDPK1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6510447 | 0.94 | PDPK1 (0.35) | PDPK1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL4536423 | 0.85 | PDPK1 (0.43) | PDPK1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL15688384 | 0.78 | HPGD (0.48) | TSHRMAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL2327689 | 0.77 | — | — | |
| SCHEMBL12051534 | 0.76 | PDPK1 (0.41) | PDPK1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL24552572 | 0.76 | PDPK1 (0.37) | PDPK1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL15334043 | 0.76 | PDPK1 (0.37) | PDPK1MAPTKDR | |
| SCHEMBL22121979 | 0.76 | ALDH1A1 (0.38) | PDPK1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30949999 | 0.76 | PDPK1 (0.37) | PDPK1TSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353853-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-11-20 | — | — | US | disclosed |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| WO-2025092989-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF | 泰州红云制药有限公司 | 2025-05-08 | — | — | WO | disclosed |
| EP-4547336-A1 | USP1 INHIBITORS AND USES THEREOF | Zentaur Therapeutics USA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119836421-A | USP1 inhibitors and uses thereof | 森韬医药美国公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119630645-A | Flavivirus inhibitors | IRBM股份公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-119019388-A | 5-And 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 英莱汶公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240245682-A1 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-20150344490-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2917219-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014072881-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014072881-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
| WO-2005105814-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | PDPK1 104/4885TSHR 1650/4885ALDH1A1 3857/4885 |
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | ARRB1, ADRA1D, ADRB1 | PDPK1 610/4885TSHR 395/4885ALDH1A1 1063/4885 |
| US-20150344490-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | ARRB1, ADRA1D, ADRB1 | PDPK1 610/4885TSHR 395/4885ALDH1A1 1063/4885 |
| US-20240245682-A1 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | ITGB8, ITGAV, ITGA8 | PDPK1 2247/4885TSHR 2304/4885ALDH1A1 1805/4885 |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | PDPK1 520/4885TSHR 3755/4885ALDH1A1 1397/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | PDPK1 104/4885TSHR 1650/4885ALDH1A1 3857/4885 |
| US-20250353853-A1 | FLAVIVIRUS INHIBITORS | SPINT2, EIF2AK2, DDX5 | PDPK1 3138/4885TSHR 4689/4885ALDH1A1 3259/4885 |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | PDPK1 520/4885TSHR 3755/4885ALDH1A1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.